Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model

Eun-Ju Choi; Hyuek Jong Lee; Wan-Jae Kim; Kwon-Il Han; Masahiro Iwasa; Kazumasa Kobayashi; Trishna Debnath; Yujiao Tang; Yi-Sub Kwak; Jin-Hwan Yoon; Eun-Kyung Kim

doi:10.1371/journal.pone.0210854

Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model

PLoS One. 2019 Feb 28;14(2):e0210854. doi: 10.1371/journal.pone.0210854. eCollection 2019.

Authors

Eun-Ju Choi¹, Hyuek Jong Lee², Wan-Jae Kim³, Kwon-Il Han³, Masahiro Iwasa³, Kazumasa Kobayashi⁴, Trishna Debnath⁵, Yujiao Tang^{6

7}, Yi-Sub Kwak⁸, Jin-Hwan Yoon⁹, Eun-Kyung Kim⁶

Affiliations

¹ Department of Physical Education, College of Education, Daegu Catholic University, Gyeongsan, Republic of Korea.
² Center for Vascular Research, Institute for Basic Science (IBS), Daejeon, Republic of Korea.
³ Research & Development Center, Korea BeRM Co. Ltd., Wonju, Republic of Korea.
⁴ Bien Co. Ltd., Sapporo, Japan.
⁵ Department of Food Science and Biotechnology, Dongguk University, Goyang, Republic of Korea.
⁶ Division of Food Bioscience, College of Biomedical and Health Sciences, Konkuk University, Chungju, Republic of Korea.
⁷ School of Bio-science and Food Engineering, Changchun University of Science and Technology, Changchun, China.
⁸ Department of Physical Education, Dong-Eui University, Busanjin-gu, Busan, Republic of Korea.
⁹ Institute for Natural Science Research, Hannam University, Daejeon, Republic of Korea.

Abstract

Recent studies have demonstrated the immunomodulatory effects of heat-killed lactic acid bacteria. The aim of this study was to evaluate the protective effect of heat-killed Enterococcus faecalis EF-2001 (EF-2001) on a model of inflammatory bowel disease (IBD). A total of 28 female NC/Nga mice were divided into 4 treatment groups. Controls were fed a normal commercial diet. In the experimental groups, colitis was induced by rectal administration of dinitrobenzene sulfonic acid. Two groups were orally administered 2 and 17 mg/kg EF-2001, respectively. EF-2001 treatment decreased the expression of several cytokines, including cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), interferon (IFN)-γ, interleukin (IL)-1β, and IL-6 in inflamed colon compared to the DNBS alone group. In addition, EF-2001 suppressed DNBS-induced colonic tissue destruction. Therefore, this study strongly suggests that EF-2001 could alleviate the inflammation associated with mouse IBD.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Benzenesulfonates / toxicity*
Colon / metabolism*
Colon / pathology
Cyclooxygenase 2 / metabolism
Cytokines / metabolism
Disease Models, Animal
Enterococcus faecalis*
Female
Inflammatory Bowel Diseases* / chemically induced
Inflammatory Bowel Diseases* / metabolism
Inflammatory Bowel Diseases* / pathology
Inflammatory Bowel Diseases* / prevention & control
Mice

Substances

Benzenesulfonates
Cytokines
dinitrobenzenesulfonic acid
Ptgs2 protein, mouse
Cyclooxygenase 2

Grants and funding

This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2017R1D1A1B03033780). This funder provided support in the form of salaries for authors T. Debnath, Y. Tang. W Kim, K Han. M Iwasa, A Ogasawara are employed by commercial company Korea BeRM Co. Ltd., who provided ‘EF-2001’. K Kobayashi is employed by commercial company Bien Co. Ltd. The funders did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.